Emerging Growth Research publie un rapport éclair sur DIAGNOS, mettant en lumière les catalyseurs réglementaires et le potentiel de commercialisation de la plateforme CARA AI

DIAGNOS announced that Emerging Growth Research published a flash report highlighting the company's progress toward key regulatory approvals for its CARA AI platform. The company is pursuing regulatory authorizations from Health Canada, FDA, and Saudi FDA, with a Health Canada submission targeted for June 10, 2026. CARA has evaluated over 400,000 patients across 140 clinics in 16 countries and detects early signs of age-related macular degeneration and diabetic retinopathy. The addressable market opportunity is estimated at approximately CAD 11 billion.